A recent study published in the journal Health and Quality of Life Outcomes revealed that the Brief Resilient Coping Scale (BRCS) is a suitable tool to assess resilience in patients with systemic lupus erythematosus (SLE). The BRCS is a self-reported measurement test considered a reliable indicator of resilience — the ability to cope…
News
Kezar Life Sciences, a San Francisco-based company focused on the development of therapies targeting protein homeostasis, recently initiated a Phase 1 clinical trial assessing KZR-616, a potential treatment for multiple autoimmune and inflammatory diseases, including lupus. Together with a medical team in Australia, the study will be performed in a…
A large number of patients with class II lupus nephritis (LN) show histological transformations years after the diagnosis, a new study reported, adding that proteinuria — or excessive amounts of protein in the urine — can serve as a predictor of patient outcome. This findings are the result of a multicenter study carried out in…
The Pharmaceutical Research and Manufacturers of America (PhRMA) and Lupus Foundation of America (LFA) released a new report highlighting the progress in the fight against autoimmune diseases, including lupus. The report, “Medicines in Development for Autoimmune Diseases: A Report on Autoimmune Diseases,” states that America’s biopharmaceutical…
Leptin, a hormone produced by fat cells in the body, was seen to actively promote systemic lupus erythematosus (SLE) in mouse models of the disease, allowing the formation of autoantibodies and changing the activities of immune cells. Patients with lupus have increased levels of leptin, but until now researchers did not know…
In a recent update on its pivotal Phase 3 clinical trial evaluating Lupuzor (rigerimod) as a potential treatment for lupus, ImmuPharma announced that it was complying with a request to open a trial site in Mauritius so that patients there could participate in the study. According to the company, the leading…
XTL Biopharmaceuticals announced that a patent has been issued covering the Europe Union for its leading drug candidate, hCDR1 (edratide), a potential treatment for systemic lupus erythematosus (SLE). The European Patent Office issue (EP1594434) is titled “Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus,” and covers formulations…
Maintaining optimal levels of vitamin D in the blood could be protective against the risk of cardiovascular disease often seen in systemic lupus erythematosus (SLE) patients, according to a large literature review conducted on the subject.
Lakeshore Recycling Systems (LRS) will join with the Lupus Society of Illinois (LSI) to raise money and disease awareness through the 2016 Chicago Illinois Lupus Walk. This year’s walk will take place on Sunday, Sept. 18, at Lincoln Park, from 9:00 a.m. to 1:00 p.m. Participants may choose distances of…
A recently released poll shows widespread public support among residents of San Jose, California, in favor of patient access to medical marijuana delivered to their homes — 63% in favor, in fact — as the City Council prepares to begin considering new regulations for businesses working in this area. Medical marijuana is…
Recent Posts
- Finding our superpower by surviving lupus flares
- Self-injected Saphnelo offers new flexibility for lupus treatment
- Chronic illness, sex, and intimacy: The conversation we’re not having
- Galápagos’ oral therapy for lupus fails to meet key trial objective
- What I learned about navigating travel anxiety with lupus